We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other Wednesday’s best-performing stocks. The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision to keep interest rates unchanged. On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impact of President Donald Trump’s tariff policies. The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent. Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday’s 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday A pharmaceutical sales rep holding a medicine pack, highlighting the drug candidate products. Tempus AI, Inc. (NASDAQ:TEM) Tempus AI saw its share prices increase by 12.59 percent on Wednesday to finish at $58.76 apiece as investors loaded portfolios following an optimistic outlook guidance, offsetting a dismal earnings performance during the past quarter. In its latest earnings release, Tempus AI, Inc. (NASDAQ:TEM) said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year. During the first quarter, Tempus AI, Inc. (NASDAQ:TEM) widened its net loss by 5.1 percent to $68 million from $64.7 million in the same period last year. Revenues, however, were higher by 75.86 percent to $255 million from $145.8 million, with Genomics contributing $193.8 million, or an 88.9 percent increased contribution year-on-year. “The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky. “Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos,” he added. Story Continues Overall, TEM ranks 5th on our list of Wednesday’s best-performing stocks. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TEM but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. View Comments
Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...